4.1 Review

Acute exacerbations of COPD: risk factors for failure and relapse

Journal

Publisher

DOVE MEDICAL PRESS LTD
DOI: 10.2147/COPD.S145253

Keywords

infections; prevention; treatment; COPD; exacerbations

Funding

  1. Boehringer Ingelheim
  2. Menarini
  3. Vivisol
  4. Astra Zeneca
  5. Guidotti-Malesci
  6. Grifols
  7. Almirall
  8. AstraZeneca
  9. Biofutura
  10. Chiesi Farmaceutici
  11. GlaxoSmithKline
  12. Menarini Group
  13. Mundipharma
  14. Novartis
  15. Zambon
  16. Bayer
  17. consultancies for Insmed
  18. Grigols
  19. Polyphor
  20. Pfizer
  21. Boehringer
  22. Lallemand
  23. Verona Pharma
  24. Farmaceutici
  25. Chiesi
  26. Dompe
  27. GSK
  28. Guidotti
  29. Teva

Ask authors/readers for more resources

Acute exacerbations are a leading cause of worsening COPD in terms of lung - function decline, quality of life, and survival. They also have a relevant economic burden on the health care system. Determining the risk factors for acute exacerbation and early relapse could be a crucial element for a better management of COPD patients. This review analyzes the current knowledge and underlines the main risk factors for recurrent acute exacerbations. Comprehensive evaluation of COPD patients during stable phase and exacerbation could contribute to prevent treatment failure and relapses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available